Aviceda Therapeutics is a private, late-stage clinical biotechnology company based in Cambridge, Massachusetts that describes itself as the world leader in glyco-immune checkpoint therapeutics. It develops immune-mediated therapies built on a glyco-mimetic nanoparticle platform that targets the interaction between sialic acids on cell surfaces and Siglec immune receptors in order to modulate aberrant inflammation. Its lead asset, AVD-104, is an intravitreally administered sialic-acid-coated nanoparticle being evaluated in the Phase 2/3 SIGLEC trial for geographic atrophy secondary to age-related macular degeneration. Aviceda is a therapeutics developer, not a software vendor: it publishes no developer program, no public API, and no machine-readable API artifacts.
Aviceda Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Ophthalmology.
Aviceda Therapeutics’ developer surface includes product news and 9 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: aviceda-therapeutics
name: Aviceda Therapeutics
description: 'Aviceda Therapeutics is a private, late-stage clinical biotechnology company based in Cambridge, Massachusetts
that describes itself as the world leader in glyco-immune checkpoint therapeutics. It develops immune-mediated therapies
built on a glyco-mimetic nanoparticle platform that targets the interaction between sialic acids on cell surfaces and Siglec
immune receptors in order to modulate aberrant inflammation. Its lead asset, AVD-104, is an intravitreally administered
sialic-acid-coated nanoparticle being evaluated in the Phase 2/3 SIGLEC trial for geographic atrophy secondary to age-related
macular degeneration. Aviceda is a therapeutics developer, not a software vendor: it publishes no developer program, no
public API, and no machine-readable API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/aviceda-therapeutics/refs/heads/main/apis.yml
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://www.avicedarx.com/media/logo/aviceda.svg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Ophthalmology
- Clinical Trials
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/aviceda-therapeutics-domain-security.yml
- type: Website
url: https://www.avicedarx.com/
- type: About
url: https://www.avicedarx.com/about-us
- type: Contact
url: https://www.avicedarx.com/contact
- type: Careers
url: https://www.avicedarx.com/careers
- type: News
url: https://www.avicedarx.com/company-updates
- type: Investors
url: https://www.avicedarx.com/investors
- type: LinkedIn
url: https://www.linkedin.com/company/aviceda-therapeutics/
- type: Twitter
url: https://twitter.com/avicedarx
- type: SecondaryMarket
url: https://forgeglobal.com/aviceda-therapeutics_stock/
x-enrichment:
date: '2026-08-06'
status: minimal
artifacts_added: 1
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Aviceda is a clinical-stage biotech developing the AVD-104 nanoparticle for geographic atrophy; its entire web presence
is a ten-page corporate brochure at avicedarx.com (sitemap.xml lists only home, technology-platform, lead-asset, pipeline,
publications, company-updates, about-us, investors, careers, contact) with no developer section, and api./developer./docs.avicedarx.com
do not resolve in DNS.
evidence:
- url: https://www.avicedarx.com/sitemap.xml
status: 200
- url: https://www.avicedarx.com/openapi.json
status: 404
- url: https://www.avicedarx.com/.well-known/agent-card.json
status: 404
checked: '2026-08-06'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →